Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach

IF 3.5 4区医学 Q2 CHEMISTRY, MEDICINAL

Drug Development Research Pub Date : 2024-06-06 DOI:10.1002/ddr.22220

Abrar Ahmad Zargar

{"title":"Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach","authors":"Abrar Ahmad Zargar","doi":"10.1002/ddr.22220","DOIUrl":null,"url":null,"abstract":"<p>Crohn's disease (CD) is a chronic and debilitating inflammatory bowel disease that affects millions of individuals worldwide. Despite the availability of various treatment options, a significant number of patients do not achieve remission or experience adverse effects with conventional therapies. Vedolizumab, a novel therapeutic agent, has emerged as a promising approach in the management of CD. Despite improvements in treatment choices, there is still a demand for medicines that are efficient and well-tolerated. Vedolizumab, a monoclonal antibody targeting α4β7 integrin, has emerged as a promising therapeutic approach for the treatment of CD. The review aims to provide a summary of vedolizumab, current treatment options, impact of vedolizumab on the patient's quality of life, mechanism of action, clinical effectiveness, safety and efficacy of vedolizumab, potential side effects or risks associated with vedolizumab therapy, and potential predictors. Furthermore, we investigate limitations and challenges associated with vedolizumab and possible future developments and medical implications. This review provides a comprehensive examination of the present data supporting vedolizumab as a possible treatment option for CD, highlighting its benefits and outlining prospective directions for future study and clinical practice improvement.</p>","PeriodicalId":11291,"journal":{"name":"Drug Development Research","volume":"85 4","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ddr.22220","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Crohn's disease (CD) is a chronic and debilitating inflammatory bowel disease that affects millions of individuals worldwide. Despite the availability of various treatment options, a significant number of patients do not achieve remission or experience adverse effects with conventional therapies. Vedolizumab, a novel therapeutic agent, has emerged as a promising approach in the management of CD. Despite improvements in treatment choices, there is still a demand for medicines that are efficient and well-tolerated. Vedolizumab, a monoclonal antibody targeting α4β7 integrin, has emerged as a promising therapeutic approach for the treatment of CD. The review aims to provide a summary of vedolizumab, current treatment options, impact of vedolizumab on the patient's quality of life, mechanism of action, clinical effectiveness, safety and efficacy of vedolizumab, potential side effects or risks associated with vedolizumab therapy, and potential predictors. Furthermore, we investigate limitations and challenges associated with vedolizumab and possible future developments and medical implications. This review provides a comprehensive examination of the present data supporting vedolizumab as a possible treatment option for CD, highlighting its benefits and outlining prospective directions for future study and clinical practice improvement.

查看原文本刊更多论文

维多单抗治疗克罗恩病：一种前景广阔的治疗方法

克罗恩病（CD）是一种使人衰弱的慢性炎症性肠病，影响着全球数百万人。尽管有多种治疗方案可供选择，但仍有相当多的患者无法获得缓解，或在接受传统疗法后出现不良反应。维多珠单抗作为一种新型治疗药物，已成为治疗 CD 的一种很有前景的方法。尽管治疗方法有所改善，但人们仍然需要高效且耐受性良好的药物。Vedolizumab是一种靶向α4β7整合素的单克隆抗体，已成为治疗CD的一种很有前景的治疗方法。本综述旨在概述维多珠单抗、目前的治疗方案、维多珠单抗对患者生活质量的影响、作用机制、临床疗效、维多珠单抗的安全性和有效性、与维多珠单抗治疗相关的潜在副作用或风险以及潜在的预测因素。此外，我们还研究了与维多珠单抗相关的局限性和挑战，以及未来可能的发展和医学影响。本综述全面考察了目前支持将韦多珠单抗作为 CD 治疗选择的数据，强调了它的益处，并概述了未来研究和临床实践改进的前瞻性方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Development Research 医学-药学

CiteScore

6.40

自引率

2.60%

发文量

104

审稿时长

6-12 weeks

期刊介绍： Drug Development Research focuses on research topics related to the discovery and development of new therapeutic entities. The journal publishes original research articles on medicinal chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, and drug delivery, formulation, and pharmacokinetics. The journal welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy, and regulatory issues involving the drug discovery and development process. In addition to full-length articles, Drug Development Research publishes Brief Reports on important and timely new research findings, as well as in-depth review articles. The journal also features periodic special thematic issues devoted to specific compound classes, new technologies, and broad aspects of drug discovery and development.